Diabetech selected by Zyvex to collaborate on continuous glucose monitoring for people with diabetes

Dallas 01 February 2006Zyvex Corporation, a molecular nanotechnology company specializing in micro and nanomanufacturing, micro-electro-mechanical systems (MEMS), and nanomaterials has selected Diabetech LP as its medical device development and commercialization partner for their wireless sensor implant targeting real-time blood glucose levels in the body. Diabetech provides the know-how and patented technologies necessary to develop the innovative patient's handheld device for not only displaying the glucose levels from the implant to the patient but also for automatically relaying that information in real-time to GlucoDYNAMIX, Diabetech's clinical management system. Diabetech will also be responsible for commercializing this leading-edge medical device technology as part of its Virtual-Loop Programme.


The collaboration is called Project GeNI, which stands for Glucose Nanobiosensor Implant. Both firms are located in the Dallas-Fort Worth Metroplex of North Texas and have been working together for the past several months in the assessment and design phase of the project.

According to Jim Von Ehr, Zyvex Chairman and CEO, "This programme leverages Zyvex's two related federally-funded programmes and Diabetech's award-winning remote patient monitoring technology to accelerate the development of a wireless, implantable device which enables continuous availability of glucose levels within the diabetic patient."

Diabetes is a big problem and only getting bigger every day. Diabetes is the seventh leading cause of death in the United States and is a disease that affects more than 225 million people worldwide. For most people, treatment of diabetes is aimed at keeping blood glucose near normal levels at all times. That is accomplished today through a painful and imperfect process of isolated patients performing 4 to 12 finger-sticks per day, which also require expensive single-use disposable blood glucose test strips, frequent spot testing of the blood, insulin injections, carefully measured food intake, exercise and more. Assuming you can simplify the process, a patient-friendly CGM system represents a clear path to improving people's lives and cost-savings in the billions of dollars.

"One of the most exciting aspects of this programme and what makes it special is that all of the technological elements required to make the fourth generation of glucose monitoring a reality appear to be already available. The challenge will be integrating these technologies and testing them to make sure we have solved not only the physiological obstacles but also those which deal with the real world including a system accepted by health plans, physicians and patients", state Kevin McMahon, President and CEO of Diabetech.

Funding to carry out this research is being generated through programme-specific grants and targeted investment.

Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]